The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to ...

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists ...

DVCon U.S. 2026 welcomes proposals for technical tutorials and short workshops that offer high-impact educational content for design and verification professionals.

The abstracts highlight Processa’s pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri), showcasing both preclinical and clinical advances.

The abstracts highlight Processa's pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri), showcasing both preclinical and clinical advances. Trials ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its research abstracts have been accepted for poster ...

Pharvaris announces acceptance of abstracts for upcoming congresses, showcasing research on oral bradykinin B2 receptor antagonists and angioedema.

Abstract: Over the past few years, Presentation Attack Detection (PAD) has become a fundamental part of facial recognition systems. Although much effort has been devoted to anti-spoofing research, ...

Download this Corporate Business Proposal Cover Design Template vector illustration now. And search more of iStock's library of royalty-free vector art that features A4 Paper graphics available for ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length ...

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025 Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer Ingelheim NANTES, France ...